Meeting
2022 ASCO Annual Meeting
Randomized phase 3 trial of IO102-IO103 plus pembrolizumab versus pembrolizumab alone in patients with previously untreated, unresectable, or metastatic melanoma.
Authors
Inge Marie Svane
National Center for Cancer Immune Therapy, CCIT-DK, Copenhagen University Hospital, Herlev, Denmark
Inge Marie Svane , Santosh M. Nair , Igor Puzanov , Caroline Robert , Jessica Cecile Hassel , Shahneen Sandhu , Anita Vedel Christiansen , Kath Lowery , Kristine Pemberton , Mohammad Al Hajj , Scott J. Diede , Eva Ehrnrooth , Alexander M. Eggermont
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
EudraCT: 2021-004594-32; ClinicalTrials.gov No: NCT05155254
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS9589)
DOI
10.1200/JCO.2022.40.16_suppl.TPS9589
Abstract #
TPS9589
Poster Bd #
182a
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
A phase III, randomized, double-blind study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus dacarbazine in patients (pts) with previously untreated, unresectable, or metastatic melanoma (MEL).
First Author: Caroline Robert
First Author: Igor Tsaur
Poster
2018 ASCO Annual Meeting
Phase II trial of pembrolizumab (pembro) plus 1 mg/kg ipilimumab (ipi) immediately following progression on anti-PD-1 Ab in melanoma (mel).
First Author: Daniel Olson
Poster
2018 Gastrointestinal Cancers Symposium
CheckMate 648: A randomized phase 3 study of nivolumab plus ipilimumab or nivolumab combined with fluorouracil plus cisplatin versus fluorouracil plus cisplatin in patients with unresectable advanced, recurrent, or metastatic previously untreated esophageal squamous cell carcinoma.
First Author: Jaffer A. Ajani